Skip Navigation LinksHome > August 2010 - Volume 29 - Issue 8 > ANTIBODY PERSISTENCE 12 MONTHS AFTER A BOOSTER DOSE OF MENIN...
Pediatric Infectious Disease Journal:
doi: 10.1097/INF.0b013e3181d9e653
Brief Reports

ANTIBODY PERSISTENCE 12 MONTHS AFTER A BOOSTER DOSE OF MENINGOCOCCAL-C CONJUGATED VACCINE IN THE SECOND YEAR OF LIFE

Diez-Domingo, Javier MD, PhD*†; Planelles-Cantarino, M. Victoria MD†; Baldo-Torrenti, Jose M. MD†; Ubeda-Sansano, Isabel MD, PhD†; Jubert-Rosich, Angels MD†; Puig-Barbera, Joan MD, PhD*; Gutierrez-Gimeno, M. Victoria PhD*

Supplemental Author Material
Collapse Box

Abstract

We report on the results of the 12-month follow-up of children aged 14 to 18 months who received primary and booster vaccinations with either a meningococcal-C vaccine conjugated to tetanus toxoid or CRM197.

Seroprotection (92.8%) and geometric mean titers/serum bactericidal activity (410.5; 95% CI: 273.4–616.3) were higher in children receiving the meningococcal serogroup C tetanus toxoid conjugate, compared with 61.5% and serum bactericidal antibody geometric mean titer of 45.1 (95% CI: 28.5–71.3) when MenC-CRM197 conjugate was used.

© 2010 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.